CHADDS FORD, Pa., Aug. 22, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq :ENDP ) announced today the appointment of Kelly Huang, Ph.D., to the position of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, an Endo subsidiary, is a leading U.S. provider of urological products and services based in Austin, Texas.
Huang will take over leadership from current HealthTronics Group President James Whittenburg, who is staying through the remainder of the year to effect a seamless transition as HealthTronics continues to provide exceptional urological products and services in improving patient care. Whittenburg joined HealthTronics in 2004, was appointed President and CEO in 2007 and became an Endo Group President in July 2010 with the acquisition of HealthTronics, Inc.
Prior to joining HealthTronics, Dr. Huang held the role of Vice President of Research & Development at Neutrogena, where he was also a member of the global Management Board. Prior to Neutrogena, Dr. Huang established and headed the Molsaic Internal Venture, a startup sponsored by Johnson & Johnson's Development Corporation. Prior to Molsaic, Dr. Huang held leadership positions within Johnson & Johnson's Consumer business, which included spending two years in Paris, France, that drove innovation globally.
"I am very pleased to announce Kelly's appointment to lead our important HealthTronics subsidiary," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "Kelly brings a wealth of experience leading global businesses through the integration of scientific, consumer and professional insights and creating value by putting the customer and patient at the center. Kelly's experiences and skills will be invaluable to Endo's continued transformation to provide integrated healthcare solutions to patients, payers and providers, as well as HealthTronics' mission to provide the most advanced technology and premier support systems to urologists, hospitals, surgery centers and clinics. I would also like to thank James Whittenburg for his contributions to Endo. Under his leadership, the HealthTronics business has become an industry leader and national provider of urological services and products."
HealthTronics, Inc. is a premier urology company providing an exclusive suite of healthcare services and technology, including urologist partnership opportunities, surgical and capital equipment, maintenance services and anatomical pathology services. The company's product portfolio includes a full line of urology equipment and products, including lithotripters, surgical lasers for treatment of BPH, and anatomical pathology services. As a service provider, HealthTronics offers the latest technology in lithotripsy services and prostate therapy services, including BPH treatments and prostate cancer treatments. For more information, visit www.healthtronics.com.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Pharmaceuticals